Citadel Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-88,520
| Closed | -$429K | – | 10887 |
|
|
2020
Q1 | $429K | Sell |
88,520
-636,786
| -88% | -$4.13M | ﹤0.01% | 6717 |
|
|
2019
Q4 | $7.71M | Buy |
725,306
+713,546
| +6,068% | +$7.08M | ﹤0.01% | 2516 |
|
|
2019
Q3 | $122K | Sell |
11,760
-345,651
| -97% | -$4.52M | ﹤0.01% | 8395 |
|
|
2019
Q2 | $5.48M | Buy |
357,411
+327,761
| +1,105% | +$4.74M | ﹤0.01% | 2969 |
|
|
2019
Q1 | $381K | Sell |
29,650
-437,870
| -94% | -$4.95M | ﹤0.01% | 7247 |
|
|
2018
Q4 | $4.44M | Sell |
467,520
-437,619
| -48% | -$5.67M | ﹤0.01% | 2958 |
|
|
2018
Q3 | $15M | Buy |
905,139
+80,065
| +10% | +$1.28M | 0.01% | 1662 |
|
|
2018
Q2 | $13.2M | Buy |
825,074
+240,201
| +41% | +$4.29M | 0.01% | 1665 |
|
|
2018
Q1 | $8.95M | Buy |
+584,873
| New | +$9.12M | ﹤0.01% | 1846 |
|
|
2016
Q1 | – | Sell |
-22,397
| Closed | -$141K | – | 8517 |
|
|
2015
Q4 | $141K | Buy |
+22,397
| New | +$182K | ﹤0.01% | 6281 |
|
|
2015
Q3 | – | Sell |
-3,891
| Closed | -$46K | – | 9412 |
|
|
2015
Q2 | $46K | Buy |
3,891
+1,295
| +50% | +$18K | ﹤0.01% | 7708 |
|
|
2015
Q1 | $38K | Buy |
2,596
+1,323
| +104% | +$20.2K | ﹤0.01% | 7568 |
|
|
2014
Q4 | $22K | Sell |
1,273
-4,798
| -79% | -$69.2K | ﹤0.01% | 7744 |
|
|
2014
Q3 | $76K | Buy |
+6,071
| New | +$74.7K | ﹤0.01% | 6628 |
|
|
2013
Q4 | – | Sell |
-156,586
| Closed | -$7.09M | – | 7253 |
|
|
2013
Q3 | $7.09M | Buy |
+156,586
| New | +$5.11M | 0.01% | 1318 |
|
Citadel Advisors's STML Position: Q2 2020 in Review
Citadel Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 88,520 shares — an estimated $429K sold.
Citadel Advisors first reported a position in STML in Q3 2013 and held it in 15 quarters. The position peaked at $15M in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Citadel Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Citadel Advisors sold 88,520 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $429K.
- Citadel Advisors first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 15 quarters.
- Citadel Advisors's Stemline Therapeutics, Inc. position peaked at $15M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.